Carregant...
Setbacks and promises for drugs against Alzheimer's disease: As pharmaceutical companies are retreating from drug development for Alzheimer's, new approaches are being tested in academia and biotech companies
The withdrawal of pharmaceutical companies from developing drugs against Alzheimer's highlights the inherent difficulties in tackling this devastating disease. In the meantime, biotech companies and basic research explore new targets and drug combinations.[Image: see text]
Guardat en:
| Publicat a: | EMBO Rep |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6123640/ https://ncbi.nlm.nih.gov/pubmed/30150324 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embr.201846714 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|